Goodman M M, Callahan A P, Knapp F F
J Med Chem. 1985 Jun;28(6):807-15. doi: 10.1021/jm00383a020.
The synthesis of a new methyl-branched fatty acid, (E)-19-iodo-3(RS)-methyl-18-nonadecenoic acid (19), is described. Methyl branching has been introduced at the 3-position to inhibit beta-oxidation and radioiodide has been attached as a trans-vinyl iodide. Preparation of 19 involved a 15-step sequence of reactions climaxing with formation of the methyl ester 18 by iododestannylation of methyl (E)-19-(tri-n-butylstannyl)-3(RS)-methyl-18-nonadecenoate (17) resulting from the reaction of n-Bu3SnH with methyl 3(RS)-methyl-18-nonadecynoate (16). Methyl branching was introduced at an early stage by Friedel-Crafts acylation of thiophene with 3(RS)-methyl-4-carbomethoxybutanoyl chloride (3) generated from 3-methylglutaric anhydride. The new agent, [125I]-19, showed high myocardial uptake (5 min, 4.89% dose/g; 30 min, 3.32% dose/g), good heart/blood (H/B) ratios (5 min, 5.4/1; 30 min, 4.3/1), and significantly greater myocardial retention in fasted rats than the corresponding straight-chain analogue 19-[125I]-iodo-18-nonadecenoic acid (5 min, 3.52% dose/g, H/B = 4.8/1; 30 min, 1.19% dose/g, H/B = 1.6/1). Excellent myocardial images were obtained in rats after administration of [123I]-19 and confirmed the slow myocardial washout over a 60-min period. These data suggest that 19 is a good candidate for evaluation of heart disease involving aberrations in fatty acid metabolism by use of imaging techniques such as single photon emission computerized tomography (SPECT) where redistribution or washout should be minimized.
本文描述了一种新的甲基支链脂肪酸,即(E)-19-碘-3(RS)-甲基-18-十九碳烯酸(19)的合成。已在3位引入甲基支链以抑制β-氧化,并以反式乙烯基碘的形式连接放射性碘。19的制备涉及15步反应序列,最终通过对(E)-19-(三正丁基锡基)-3(RS)-甲基-18-十九碳烯酸甲酯(17)进行碘脱锡反应形成甲酯18,而17是由正丁基三丁基锡烷(n-Bu3SnH)与3(RS)-甲基-18-十九碳炔酸甲酯(16)反应生成的。甲基支链是在早期通过噻吩与由3-甲基戊二酸酐生成的3(RS)-甲基-4-甲氧基羰基丁酰氯(3)进行傅克酰基化反应引入的。新型试剂[125I]-19显示出高心肌摄取(5分钟时为4.89%剂量/克;30分钟时为3.32%剂量/克)、良好的心脏/血液(H/B)比率(5分钟时为5.4/1;30分钟时为4.3/1),并且在禁食大鼠中其心肌保留率明显高于相应的直链类似物19-[125I]-碘-18-十九碳烯酸(5分钟时为3.52%剂量/克,H/B = 4.8/1;30分钟时为1.19%剂量/克,H/B = 1.6/1)。给大鼠注射[123I]-19后获得了出色的心肌图像,并证实了在60分钟内心肌清除缓慢。这些数据表明,19是通过单光子发射计算机断层扫描(SPECT)等成像技术评估涉及脂肪酸代谢异常的心脏病的良好候选物,在这些技术中,再分布或清除应降至最低。